New hope for aggressive lymphoma: targeted drug combo enters trial

NCT ID NCT06517511

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug selinexor to standard chemotherapy (R-CHOP) can improve outcomes for people with a specific, hard-to-treat type of lymphoma (TP53-mutated DLBCL) who have not had prior treatment. About 42 adults aged 18-80 will receive the combination, followed by maintenance selinexor. The main goal is to see how many patients achieve complete remission, with secondary goals including survival and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Sun yat-sen university cancer center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.